Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AKB-9778: Additional Phase IIa data

Additional data from the double-blind, U.S. Phase IIa TIME-2 trial in 144 patients with DME showed

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE